Connect with us

Published

on

Spotify’s Co-founder and CEO Daniel Ek attends a live recording panel at Acquired, a technology podcast, at the Chase Center in San Francisco, California, U.S., Sept. 10, 2024.

Laure Andrillon | Reuters

Spotify shares climbed 10% on Tuesday after the music streaming company recorded its first full year of profitability, closing the fiscal year with 1.14 billion euros in net income.

Here are the numbers from its fourth-quarter earnings report, compared with analyst expectations:

  • Revenue: 4.24 billion euros vs. 4.19 billion euros expected by analysts polled by LSEG
  • Earnings per share: 1.76 euros vs.1.99 euros expected by analysts polled by LSEG
  • MAUs (monthly active users): 675 million vs. 664.3 million expected by analysts polled by StreetAccount

The Luxembourg-based company reported a 40% growth year over year for gross profit, rising 10% from the previous quarter. Operating income came in at 477 million euros, slightly below guidance.

The company said it paid a record $10 billion in royalties to the music industry in 2024, growth that’s likely to continue with the streamer’s new multiyear publishing agreement with Universal Music Group announced in January.

The deal will include new paid subscription tiers, bundles for music and nonmusic content and a direct license between the two companies for Spotify in the U.S. and other countries.

Read more CNBC tech news

Spotify Wrapped continued to be one of the biggest user engagement drivers of the year, with the annual December listening analysis helping deliver year-over-year growth.

The company said its 35 million net growth of MAUs was a fourth-quarter record. MAUs were up 5% since last quarter and 12% for the year.

Spotify reported net income of 367 million euros in the fourth quarter, or $1.81 per share, an improvement from the previous quarter and well above the net loss of 70 million euros from the year-ago quarter, a loss of 36 cents per share.

Fourth-quarter revenue of 4.24 billion euros was well above the 3.67 billion in revenue from the same quarter a year ago.

First-quarter guidance estimates the company will have 678 million MAUs, a net add of 3 million, with two-thirds expected to be premium paid subscribers. Total revenue is estimated at 4.2 billion euros, outperforming LSEG-surveyed analysts’ expectations at 4.17 billion.

Spotify stock is up more than 20% year to date.

Continue Reading

Technology

Jim Cramer: Patient Apple bulls are vindicated, and the stock is just getting started

Published

on

By

Jim Cramer: Patient Apple bulls are vindicated, and the stock is just getting started

Continue Reading

Technology

What Jim Cramer expects from Boeing, and why he says Starbucks is a buy

Published

on

By

What Jim Cramer expects from Boeing, and why he says Starbucks is a buy

Continue Reading

Technology

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Published

on

By

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025.

Gerry Miller | CNBC

Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery. 

Claude for Life Sciences is built around Anthropic’s existing AI models, but supports new connections with other scientific tools that are commonly used in labs during research and development.

It will be able to help researchers through all stages of the discovery process, from carrying out literature reviews to developing hypotheses, analyzing data, drafting regulatory submissions and more, Anthropic said.

The launch of Claude for Life Sciences marks Anthropic’s first formal entry into the sector, and comes just months after the company hired longtime industry executive Eric Kauderer-Abrams as its head of biology and life sciences. 

“Now is the threshold moment for us where we’ve decided this is a big investment area,” Kauderer-Abrams told CNBC in an interview. “We want a meaningful percentage of all of the life science work in the world to run on Claude, in the same way that that happens today with coding.”

Read more CNBC tech news

Anthropic, which is one of the companies at the center of the AI boom, develops a family of large language models called Claude. It was founded in 2021 by a group of former OpenAI executives and researchers, and its valuation has swelled to $183 billion in just four years.

The company launched a new model, Claude Sonnet 4.5, late last month and said it is “significantly better” at life sciences tasks like understanding laboratory protocols.  

Kauderer-Abrams said researchers have already been engaging with Anthropic’s models to help with isolated parts of the scientific process, so the company decided to formally build out Claude for Life Sciences as a way to support them from start to finish. 

That meant Anthropic had to establish integrations with key players in the life sciences ecosystem, including Benchling, PubMed, 10x Genomics and Synapse.org, among others. Anthropic has also partnered with companies that can help life sciences organizations adopt AI, like Caylent, KPMG, Deloitte, and cloud providers AWS and Google Cloud, the company said.

“We’re willing and enthusiastic about doing that grind to make sure that all the pieces come together,” Kauderer-Abrams said.

In a prerecorded demo, Anthropic showed how a scientist working on preclinical studies could use Claude for Life Sciences to compare two study designs that test different dosing strategies. 

The scientist was able to query her lab’s data directly from Benchling, generate a summary and tables of key differences with links back to the original material. After reviewing the results, the scientist generated a study report that could be included in a regulatory submission. 

Anthropic said an analysis like this used to require “days” of validating and compiling information, but now, it can be done in minutes. 

Kauderer-Abrams said the company believes AI can bring about real efficiency gains for the life sciences sector, but it’s also under “no illusions” that it will magically overcome the physical limitations of conducting scientific research. Clinical trials that take three years are not suddenly going to take one month, he said.

Instead, Anthropic is focused on exploring the time-consuming, expensive parts of the discovery process “piece by piece” to determine where AI could be most useful.

“We’re here to make sure that this transformation happens and that it’s done responsibly,” Kauderer-Abrams said.

WATCH: Anthropic launches Claude Sonnet 4.5, its latest AI model

Anthropic launches Claude Sonnet 4.5, its latest AI model

Continue Reading

Trending